Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
TMAC Music Acquisition Corp
AFL Aflac Inc
IGC India Globalization Capital Inc
KSM DWS Strategic Municipal Income Trust
CNC Centene Corp
WPM Wheaton Precious Metals Corp
HPX^ HPX Corp
KRNLU Kernel Group Holdings Inc
$TFRRU1000GCADL Russell 1000 Growth CAD Total Return
Go

Longeveron Inc., formerly Longeveron LLC, is a clinical stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. Its lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring clinical trials in various indications, including Aging Frailty, Alzheimer's disease (AD), the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS) and hypoplastic left heart syndrome (HLHS). It is developing Lomecel-B as a therapy for Aging Frailty and is being designed to reduce inflammation associated with Aging Frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. It is conducting two multicenter trials in the United States (U.S.)

Price: Delayed
$17.94

Day's Change: -2.49 (-12.19%)

Bid: --

Ask: --

B/A Size: --

Day's High: 21.50

Day's Low: 17.65

Volume (Light) Today's volume of 1,670,554 shares is on pace to be much lighter than LGVN's 10-day average volume of 68,785,333 shares.: 1,670,554

Yesterday's News, December 01, 2021
3:16 am ET	Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that it entered into a securities purchase...(Globe Newswire)
November 30, 2021
3:20 pm ET	Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today that it has entered into a...(Globe Newswire)
8:45 am ET	Increased Prevalence of Atopic Dermatitis Fueling Impressive Growth for Atopic Dermatitis Drugs FinancialNewsMedia.com News Commentary - Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is...(PR Newswire)
8:45 am ET	Increased Prevalence of Atopic Dermatitis Fueling Impressive Growth for Atopic Dermatitis Drugs FinancialNewsMedia.com News Commentary - Atopic dermatitis is a chronic inflammatory skin condition characterized by red, itchy, swollen, and broken skin. White fluid can leak from the affected region, necessitating treatment. The atopic dermis is...(PR Newswire)
November 18, 2021
8:00 am ET	U.S. Food and Drug Administration Approves Longeveron's Lomecel-B for Rare Pediatric Disease Designation to Treat Life-Threatening Infant Heart Condition Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food and Drug Administration...(Globe Newswire)
November 14, 2021
11:55 pm ET	FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / November, 14 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ:LGVN) for...(Accesswire)
November 12, 2021
2:22 pm ET	FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Los Angeles, California--(Newsfile Corp. - November 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ...(Newsfile)
11:02 am ET	Last Few Hours to Actively Participate in Longeveron Inc. (LGVN) Class Action - Bronstein, Gewirtz & Grossman, LLC NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ:LGVN) and certain of its officers...(Accesswire)
10:50 am ET	LGVN Deadline Alert: Rosen, A Leading Law Firm, Encourages Longeveron Inc. Investors to Secure Counsel Before Important Deadline Today in Securities Class Action - LGVN New York, New York--(Newsfile Corp. - November 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or traceable to the Offering documents...(Newsfile)
8:00 am ET	DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / November 12, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ:LGVN) for...(Accesswire)
8:00 am ET	Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding the status of the...(Globe Newswire)
November 11, 2021
6:55 pm ET	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline - LGVN NEW YORK, NY / ACCESSWIRE / November 11, 2021 / Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers. The class action, filed in the...(Accesswire)
November 10, 2021
2:55 pm ET	DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Los Angeles, California--(Newsfile Corp. - November 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ...(Newsfile)
1:15 pm ET	NOVEMBER 12, 2021 LAWSUIT DEADLINE REMINDER FOR LONGEVERON INC. (NASDAQ: LGVN) SHAREHOLDERS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Longeveron Inc. Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021 in a securities class action lawsuit that has been filed on behalf of investors...(Globe Newswire)
10:45 am ET	FINAL DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Longeveron Inc. Investors with LARGE LOSSES to Secure Counsel Before Important November 12 Deadline in Securities Class Action - LGVN NEW YORK, NY / ACCESSWIRE / November 10, 2021 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ:LGVN): (1) pursuant and/or traceable to the Offering documents issued in...(Accesswire)
10:00 am ET	Last Days to Actively Participate in Longeveron Inc. (LGVN) Class Action - Bronstein, Gewirtz & Grossman, LLC New York, New York--(Newsfile Corp. - November 10, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its...(Newsfile)
November 09, 2021
3:06 pm ET	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming Deadline - LGVN Pomerantz LLP announces that a class action lawsuit has been filed against Longeveron Inc. ("Longeveron" or the "Company") (NASDAQ: LGVN) and certain of its officers. The class action, filed in the United States District Court for the Southern...(Globe Newswire)
2:49 pm ET	FRIDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Los Angeles, California--(Newsfile Corp. - November 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ: LGVN)...(Newsfile)
1:55 pm ET	FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm LOS ANGELES, CA / ACCESSWIRE / November 9, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Longeveron Inc. ("Longeveron" or "the Company") (NASDAQ:LGVN) for violations...(Accesswire)
1:16 pm ET	NOVEMBER 12, 2021 LAWSUIT DEADLINE REMINDER FOR LONGEVERON INC. (NASDAQ: LGVN) SHAREHOLDERS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Longeveron Inc. NEW YORK, NY / ACCESSWIRE / November 9, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion no later than November 12, 2021, in a securities class action...(Accesswire)
Next >

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and